A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07594587
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
0 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Key Dates

Start date
May 11, 2026
Status verified
Jun 2026
Primary completion
May 15, 2030
Completion
May 15, 2030

Study Design

Enrollment
395 participants (estimated)

Arms

  • Arm: Ruxolitinib Cohort
    Patients with acute and chronic GVHD treated with ruxolitinib.

Primary Outcome Measure

Number and Percentage of Patients With Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥ 3 Infections [ Time Frame: Up to 1 year ]

Central Contacts

Related Studies